Collateral for a security interest recorded Oct 19, 2022 (Orbimed Royalty & Credit Opportunities IV, LP).
Term ends Jan 21, 2035 · Low confidence
20-year base term ends Jan 21, 2035
Held by AstraZeneca AB
Filed Apr 22, 2020 as application 16/855,522 · Granted Sep 14, 2021
Base term, 20 years from filing
Today
2015
2035
Clock starts
Jan 21, 2015
Jan 21, 2015
Term ends
Jan 21, 2035
Jan 21, 2035
Granted
Sep 14, 2021
Sep 14, 2021
base term
fee events
Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
None
Term adjustment
No prosecution delay on this record.
No effect
Terminal disclaimer
Resolved from the filed document, referencing US 10,287,258, US 10,669,245, US 9,522,894, US 9,815,805, to Jan 21, 2035. The term already ends on or before that date, so the cap shortened nothing.
1 of 3
Maintenance fees paid
Three maintenance fees fall due, at 3.5, 7.5 and 11.5 years from grant. This counts the ones the record shows paid.
19
Family applications on record here
Applications sharing this one's continuity chain whose file history this site holds. The family may have others.
This patent's term is its 20-year base term, with no adjustment for prosecution delay. A terminal disclaimer is resolved from the filed document, and it ends no earlier than this term, so it shortens nothing. 1 of 3 maintenance fees is paid so far. Confidence: Low. from the record
How we calculated this date
One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Jan 21, 2015, when application 14/601,371, the earliest non-provisional in its chain, was filed (this one was filed Apr 22, 2020); a parent in its chain could not be resolved (the next row) | Jan 21, 2035 | High confidence |
| Continuity chain | A parent in the chain could not be resolved | dated from this application's own claim | Medium confidence |
| Patent term adjustment | None on file | no change | High confidence |
| Terminal disclaimer cap | Disclaimer resolved from the filed document (refs US 10,287,258, US 10,669,245, US 9,522,894, US 9,815,805) | resolves to Jan 21, 2035, no earlier than this term, so no change | High confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 1 of 3 maintenance fees paid | In force | High confidence |
| Further caveats on record | The record names parents not resolved: 15708634, 15346411, 15708634, 15346411 | Low confidence overall | Low confidence |
| Computed term end | The steps above, in order | Jan 21, 2035 | Low confidence |
This family
| US 9,522,894 | In force Mar 2035 | Mar 2035 |
| US 9,815,805 | In force Jan 2035 | Jan 2035 |
| US 10,287,258 | In force Jan 2035 | Jan 2035 |
| US 10,669,245 | In force Jan 2035 | Jan 2035 |
| US 11,117,874 | this patent Jan 2035 | Jan 2035 |
| US 11,667,615 | In force Jan 2035 | Jan 2035 |
| US 11,773,069 | In force Jan 2035 | Jan 2035 |
| US 11,655,221 | In force Jan 2035 | Jan 2035 |
8 of 19 applications in this family shown, earliest filings first. The applications whose file history this site holds. The family may have others.
Assignments
Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Apr 30, 2020 Reel 52540, frame 905 | Doyle, Kevin; Van De Poel, Amanda; Jones, Graham; Watson, David; Macritchie, Jaqueline; Palmer, Nicholas | Biofocus Dpi Ltd. | Assignment of Assignor's Interest |
| Apr 30, 2020 Reel 52540, frame 957 | Connolly, Stephen; Swallow, Steven | AstraZeneca UK Limited | Assignment of Assignor's Interest |
| Apr 30, 2020 Reel 52541, frame 66 | Lonn, Hans Roland; Ponten, John Fritiof; Aurell, Carl-johan; Po Karlsson, Staffan | AstraZeneca AB | Assignment of Assignor's Interest |
| May 4, 2020 Reel 52564, frame 421 | Biofocus Dpi Ltd. | AstraZeneca AB | Assignment of Assignor's Interest |
| May 6, 2020 Reel 52585, frame 512 | AstraZeneca UK Limited | AstraZeneca AB | Assignment of Assignor's Interest |
| Feb 22, 2021 Reel 55350, frame 264 | Lönn, Hans Ronald; Pontén, John Fritiof; Aurell, Carl-johan; Karlsson, Staffan Po | AstraZeneca AB | Corrective Assignment to Correct the Name of Inventors Hans Roland LÖNN and John Fritiof Pontén Previously Recorded on Reel 052541 Frame 0066. Assignor(S) Hereby Confirms the Assignment. |
| Oct 19, 2022 Reel 61727, frame 39 | Insmed Incorporated | Orbimed Royalty & Credit Opportunities IV, LP | Second Lien Patent Security Agreement |
| Oct 20, 2022 Reel 61735, frame 875 | Insmed Incorporated | Biopharma Credit PLC | Patent Security Agreement |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
What's changing
Jan 2035
Term ends Jan 21, 2035. Maintenance fees still fall due before then
Terminal disclaimer
A terminal disclaimer resolved from the filed document, referencing US 10,287,258, US 10,669,245, US 9,522,894, US 9,815,805, ends no earlier than this term, so it caps nothing.
Citations
30
later US patents cite this one
That is top 5% of utility patents granted in 2021 in our data, the only group it is compared against.
How we rank
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
In force means the term is running and no lapse is on record. It is not a finding that the patent is valid.